Epicutaneous Advantage DBV's Viaskin epicutaneous immunotherapy platform positions the company as a partner for biotech and pharmaceutical groups seeking skin-based immunotherapies. The near-term milestone of delivering an EPIT treatment for peanut allergy, alongside ongoing exploration of other immunologic indications, creates licensing and collaboration opportunities across research, development, and commercialization.

Indication Expansion Beyond peanut allergy, DBV is evaluating inflammatory and autoimmune diseases. This broadens the addressable market and enables co-development or licensing deals with partners seeking novel skin-based or immunomodulatory therapies.

Commercial Readiness Recent appointments in commercial leadership and independent governance suggest the company is advancing toward commercialization readiness. This creates opportunities to engage on go-to-market strategies, payer access, and global distribution partnerships.

Capital Flexibility An active capital program and ongoing fundraising activity signal financial flexibility to fund clinical, regulatory, and scaling efforts. Potential partners can align on milestone-based financing, co-development funding, or strategic investments.

Global Footprint Headquartered in France with global investor engagement and a roadmap for broad market access, DBV offers opportunities to collaborate with European and US entities on clinical execution, manufacturing partnerships, and regulatory pathway optimization for EPIT products.